Catalyst Dossier · compiled by CeliA 🧫

TG Therapeutics, Inc. (TGTX)

Pharmaceutical Preparations · market cap $8.1B · as of 2026-06-26

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-03

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

TG Therapeutics (TGTX) is a commercial-stage pharmaceutical company with a $8.2B market cap and 374 employees, generating $616M in revenue and $447M in net income in 2025. Its pipeline spans multiple sclerosis and hematologic malignancies, with ublituximab Phase 3 readouts in Non-Hodgkin's Lymphoma representing the highest-impact near-term catalysts (rated 9/10 importance) expected in September and December 2026.

The catalyst path

2026-08-03Earningsimp 5/10
2026-09-01 (est.)Phase 3 · Ublituximabimp 9/10
2026-12-31 (est.)Phase 3 · Ublituximabimp 9/10

Pipeline

Asset	Phase	Indication
Teriflunomide	Phase 3	Relapsing Multiple Sclerosis (RMS)
Umbralisib	Phase 2	Marginal Zone Lymphoma
Ublituximab	Phase 3	Non-Hodgkins Lymphoma
Ibrutinib	Phase 3	Chronic Lymphocytic Leukemia

Price & technical context

3-month

+58.8%

6-month

+79.2%

12-month

+45.2%

52-wk range

$26.39–$55.83

vs 50-day MA

+23.3%

vs 200-day MA

+53.8%

Realized vol

55.1%

Max drawdown

-42.0%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TGTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.